YAP1 and lung carcinoma: Consistently, we found that co-treatment with the chemotherapeutic agent doxorubicin and the YAP1-TEAD inhibitor verteporfin, or knockdown of YAP expression with siYAP1, improved the efficacy of doxorubicin in lung carcinoma cells in a synergistic manner.